Petrelintide
No brand name yet
Zealand Pharma's once weekly amylin analog, developed with Roche. Phase 2 gave weight loss near 10 percent with digestive side effects close to placebo; three phase 3 trials started in September 2026.
Petrelintide comes from Zealand Pharma and sits in the Amylin class on the board. Route: weekly injection. Use tracked here: Overweight and obesity, with or without type 2 diabetes or cardiovascular disease. It stands at Phase 3 on the board, with 1 news move logged; the latest is dated 26 Oct 2026.
- 05ApprovedCleared for sale in at least one major market for this use.
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Here now
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Zealand Pharmawith Roche
- Mechanism
- Long acting amylin analog that signals fullness and slows stomach emptying
- Given as
- weekly injection
- Lead use on the board
- Overweight and obesity, with or without type 2 diabetes or cardiovascular disease
- Moves logged
- 1latest 7 days ago
Petrelintide news moves
-
Petrelintide phase 3 begins as Zealand and Roche bank two phase 2 readouts
Three ZUPREME trials with about 7,000 planned participants test the amylin analog against placebo. Phase 2 gave weight loss near 10 percent with digestive side effects close to placebo.
Other amylin molecules on the board, with their current stage.